CHICAGO (Reuters) - The effects of swine flu are already showing up in higher profits for makers of vaccines and antiviral drugs as the first pandemic of the 21st century makes its way onto corporate bottom lines.
Vaccine and flu drug orders lifted drugmaker GlaxoSmithKline to a better-than expected quarterly profit, the company said on Wednesday. Sales of the antiviral drug Relenza jumped nearly 2,000 percent compared to a year ago as governments stocked up to fight the pandemic. Glaxo predicts flu vaccine sales will spur second-half strength.
Already a subscriber? Log in.
Limited time offer:
Just RM5 per month.
Cancel anytime. No ads. Auto-renewal. Unlimited access to the web and app. Personalised features. Members rewards.
Follow us on our official WhatsApp channel for breaking news alerts and key updates!
